Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05745064 · ClinicalTrials.gov registry record · Phase 2
A Study of TL-925 as a Treatment for Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 4
- Study locations
NCT05745064: Completed Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.
NCT05745064 is a Phase 2 study of Dry Eye Disease that has completed, run by Telios Pharma. The registered enrollment target is 107 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05745064, a Phase 2 study of Dry Eye Disease, has completed, sponsored by Telios Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 4
- Study locations
Study Summary
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-925
Study Locations (4)
California
- Aesthetic Eye Care - Newport Beach
Colorado
- Vision Institute - Colorado Springs
Indiana
- Michael Washburn Center for Ophthalmic Research, LLC. - Indianapolis
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 2 |
What the finished NCT05745064 record still lists
NCT05745064 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05745064 reports a single indexed study location in California, Colorado, Indiana.
Frequently Asked Questions
What is clinical trial NCT05745064 about?
NCT05745064 is a clinical study titled "A Study of TL-925 as a Treatment for Dry Eye Disease". In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bila...
What is the current status of trial NCT05745064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2023-02-27. Estimated completion is 2023-07-11.
What conditions does trial NCT05745064 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT05745064?
The interventions under investigation include: Placebo (DRUG), TL-925 (DRUG).
Who is sponsoring clinical trial NCT05745064?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05745064 being conducted?
This trial has 4 study locations across California, Colorado, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05745064's enrollment target sits among peer trials
107 21st of 33 higher than 13 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI